# Tiotropium + Olodaterol

## Spiolto Respimat 2.5/2.5mcg/puff

| TAH Drug Code      | [ESPOT](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=ESPOT)                                                                                                                                                                                                                                                                                                                                   |
|:-------------------|:---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | a long term maintenance treatment of patients with Chronic Obstructive Pulmonary Disease, including chronic bronchitis and emphysema.                                                                                                                                                                                                                                                                    |
| Dosing             | Adults: The recommended dose is 5 mcg tiotropium and 5 mcg olodaterol (2 puffs) QD, at the same time of the day. SPIOLTOR RESPIMAT should not be used more frequently than once daily. Age < 18 years: Usually will not use.                                                                                                                                                                             |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                            |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                            |
| Contraindications  | Hypersensitivity to the active substances or to any of the excipients. History of hypersensitivity to atropine or its derivatives, e.g. ipratropium or oxitropium.                                                                                                                                                                                                                                       |
| Adverse Effects    | Common Musculoskeletal: Backache (3.6% ) Respiratory: Nasopharyngitis (12.4% ) Serious Cardiovascular: Disorder of cardiovascular system (3% or less ), Electrocardiogram abnormal Immunologic: Hypersensitivity reaction (3% or less ) Ophthalmic: Angle-closure glaucoma, Worsening (3% or less ) Renal: Urinary retention, Worsening (3% or less ) Respiratory: Bronchospasm (3% or less ), Pneumonia |
| Pregnancy          | No (Limited) Human Data â€“ Animal Data Suggest Low Risk                                                                                                                                                                                                                                                                                                                                                   |
| Lactation          | No (Limited) Human Data - Probably Compatible                                                                                                                                                                                                                                                                                                                                                            |

